Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Lexaria Bioscience Corp
LEXX
Alternate Symbol(s):
LEXXW
Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the...
bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LEXX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(18)
•••
shawk
X
Post by
shawk
on Dec 02, 2024 11:42am
Special Report-Ted Ohashi
552Let_039_sTokeBusinessNovember222024.pdf
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 30, 2024 11:01am
New Press Release - BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2024) - On FOX Business News broadcast on Sunday, Dec 1, 2024 - BTV Business Television interviews emerging companies in the markets including: Cannot view this video? Visit: https://www.b-tv.com/post/btv-features-these-stocks...
read article.
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 02, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
•••
Jonathon Brown
X
Post by
Jonathon Brown
on Nov 28, 2024 5:55am
Buzz on the Bullboards: Stocks to watch in volatile times.
The TSX hit another record high on strong retail sales data and positive investor sentiment. However, the index quickly fell from grace.
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 26, 2024 9:20am
New Press Release - Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to comeKELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 25, 2024 9:01am
New Press Release - Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
(TheNewswire)DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose formatKelowna, British Columbia – TheNewswire - November 25, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased...
read article.
(1987)
•••
lscfa
X
Comment by
lscfa
on Nov 20, 2024 5:08pm
RE:New Press Release - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
CBD with Lexaria tech outperforms weight loss drug Rybelsus in mice. Hope it's the same in human studies.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2024 9:06am
New Press Release - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
(TheNewswire)- DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.- DehydraTECH...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2024 9:05am
New Press Release - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.DehydraTECH-semaglutide...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 9:10am
New Press Release - Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
(TheNewswire)World’s First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 MoleculesKelowna, British Columbia – November 14, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 13, 2024 9:20am
New Press Release - Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
(TheNewswire)DehydraTECH clinical test article manufacturing has been completedKelowna, British Columbia – TheNewswire - November 13, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2024 9:15am
New Press Release - Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
(TheNewswire)DehydraTECH™ for GLP-1 being optimized for global pharmaceutical useKelowna, British Columbia – TheNewswire - November 7, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms provides the following glucagon...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2024 9:10am
New Press Release - Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
(TheNewswire)DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groupsKelowna, British Columbia – October 24, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 22, 2024 9:21am
New Press Release - Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
(TheNewswire)DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groupsKelowna, British Columbia – October 22, 2024 – TheNewswire...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 16, 2024 4:00pm
New Press Release - Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(TheNewswire)Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 15, 2024 8:25am
New Press Release - Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
(TheNewswire)Kelowna, British Columbia – October 15, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of...
read article.
(18)
•••
shawk
X
Post by
shawk
on Oct 10, 2024 12:33pm
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (accesswire.com)
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden